GSK 2983559

Drug Profile

GSK 2983559

Alternative Names: GSK2983559

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Receptor-interacting protein serine-threonine kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 06 Dec 2017 Chemical structure information added
  • 30 Nov 2017 Preclinical trials in Inflammatory bowel disease in United Kingdom (PO) before November 2017 (NCT03358407)
  • 30 Nov 2017 GlaxoSmithKline plans a phase I trial for Inflammatory bowel disease (In volunteers, In adults, In the elderly) (PO) (NCT03358407)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top